Clinical Trials Browser

Phase 1 × Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

260 enrolled 52 charts

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

Clinical Trials

MK-1454-001

KEYVIBE-001

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

MK-3475-A17

MK-6598-001

KEYNOTE-A33

KEYNOTE-651

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

MK-3475-028

MK-3475-032

AdenONCO

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

KEYNOTE 173

KEYNOTE-001

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone